

# Conversion of isomeric 2:3 adducts (aminoacid–formaldehyde) to *N*-acyl-pseudoprolines derivatives

Jimmy Sélambarom,<sup>a,\*</sup> Jacqueline Smadja<sup>a</sup> and André A. Pavia<sup>b</sup>

<sup>a</sup>Laboratoire de Chimie des Substances, Naturelles et des Sciences des Aliments, Faculté des Sciences and Technologies, Université de La Réunion, BP 7151, F-97715 Saint-Denis Messageries Cedex 9, France (DOM)

<sup>b</sup>Emeritus professor of the University Montpellier II, France


Received 1 October 2004; revised 24 November 2004; accepted 26 November 2004

**Abstract**—Reaction of acyl chlorides or acid anhydrides with isomeric 2:3 adducts derived from condensation of L-serine (**1a**), L-threonine (**1b**) and L-cysteine (**1c**) methyl esters with formaldehyde afforded *N*-acyl-pseudoprolines **7–19** in various yields. These 2:3 adducts can be considered as synthetic equivalents of oxaproline and thiaproline moieties. The present work revealed the versatile behaviour of the two 2:3 adducts as a consequence of the ring-chain tautomerism occurring in the five- and/or seven-membered rings.

© 2004 Elsevier Ltd. All rights reserved.

Condensation of carbonyl compounds ( $R^1 \neq H$  and/or  $R^2 \neq H$ ) with primary  $\beta$ -hydroxyamine moieties afforded *NH*-free oxazolidines type **2** ( $X = O$ : oxaproline) (Scheme 1), which are generally poorly stable and non-isolable. The latter proved to exist as a tautomeric mixture with the imine open-chain forms type **3**,<sup>1</sup> in contrast to sulfur derivatives ( $X = S$ : thiaproline).<sup>2</sup> Depending on the experimental conditions, condensation of formaldehyde ( $R^1 = H$  and  $R^2 = H$ ) has been reported to afford isomeric 2:3 adducts:<sup>3</sup> *N,N*-methylenebis(oxazolidine) derivatives type **5** ( $X = O$ ) and/or isomeric 1,6-diaza-3,9-dioxabicyclo[4.4.1]undecane structures type **6** ( $X = O$ ), instead of the expected oxazolidines type **4** ( $X = O$ ).

Common strategic routes to *N*-substituted pseudoprolines are prone to ring-chain tautomerism and/or competing reactions.<sup>4</sup> In a recent paper, we reported that 2:3 adducts **5b** ( $X = O$ ;  $R = CH_3$ ) and/or **6b** ( $X = O$ ;  $R = CH_3$ ) derived from L-threonine methyl ester **1b** could be converted into *N*-acyloxaprolines **13** and **14**,<sup>5</sup> which are usually prepared by cyclocondensation of *N*-monoacylated aminoesters with carbonyl compounds. Such observation prompted us to examine the scope of this approach, since these *N*-acyl derivatives have poten-



**Scheme 1.** Reagents and conditions: (i)  $R^1R^2C=O$ ,  $Et_3N$ ,  $CH_2Cl_2$ , rt; (ii)  $(HCHO)_3$ ,  $Et_3N$ ,  $CH_2Cl_2$ , rt; (iii)  $R'COCl$ ,  $Na_2CO_3$ ,  $H_2O/CH_3CN$ .

tial in various fields<sup>6,7</sup> including development of peptides mimics.<sup>8</sup> The procedure has now been investigated on similar and easily accessible 2:3 adducts **6a**<sup>9</sup> ( $X = O$ ;  $R = H$ ) and **5c**<sup>10</sup> ( $X = S$ ;  $R = H$ ) derived from L-serine methyl ester **1a** and L-cysteine methyl ester **1c**, respectively.

**Keyword:** *N*-Acyl-pseudoprolines.

\* Corresponding author. Tel.: +33 262 938 619; fax: +33 262 938 183; e-mail: j.selamb@univ-reunion.fr

Table 1.


Starting 2:3 adducts	X	R	R'	Product	Yield (%)
<b>6a</b>	O	H	CH <sub>3</sub>	<b>7</b>	31
	O	H	C <sub>6</sub> H <sub>5</sub>	<b>10</b>	6
<b>5b</b> and/or <b>6b</b>	O	CH <sub>3</sub>	CH <sub>3</sub>	<b>13</b>	70 <sup>5</sup>
	O	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	<b>14</b>	60 <sup>5</sup>
	O	CH <sub>3</sub>	<i>p</i> -OMe-C <sub>6</sub> H <sub>4</sub>	<b>15</b>	54
	O	CH <sub>3</sub>	<i>p</i> -NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	<b>16</b>	58
<b>5c</b>	S	H	CH <sub>3</sub>	<b>17</b>	71
	S	H	C <sub>6</sub> H <sub>5</sub>	<b>18</b>	83
	S	H	<i>p</i> -OMe-C <sub>6</sub> H <sub>4</sub>	<b>19</b>	56

The reaction was performed in water/acetonitrile at room temperature overnight with various acylating agents according to previous procedure<sup>5</sup> and the results listed in Table 1. All products were isolated on silica gel column chromatography and gave satisfactory spectroscopic data.<sup>11</sup> Mass spectrum in positive FAB ionization mode displayed the molecular ion [M+H]<sup>+</sup> and the fragments [M+H-R'C=O]<sup>+</sup> and [R'C=O]<sup>+</sup> resulting from the amide bond scission. As already reported for compounds **13** and **14**,<sup>5</sup> <sup>1</sup>H NMR spectra of the novel compounds **7**, **10** and **15–19** displayed the expected deshielding of intracyclic protons that are closed to the N-C=O grouping and the duplication of NMR signals reflecting the existence of two *syn/anti*-rotational isomers (Scheme 1). This was confirmed by NMR signals coalescence upon raising temperature.

As shown in Table 1, condensation with 2:3 adduct **5c** afforded compounds **17–19** in satisfactory yields (56–83%). The latter were very closed to those obtained when starting from the thiaproline **4c** (X = S; R = H). Therefore, the potential of this procedure seemed to be confirmed.

For L-threonine derivatives **5b/6b**, the conversion occurred with yields ranging from 54% to 70%. Similar yields (±5%) were obtained when starting from either pure isomers **5b** and **6b** or from the equilibrium mixture, thus allowing to bypass the separation step. In contrast, using the same conditions, isomer **6a** afforded a mixture of *N*-acylated and *N,O*-diacylated by-products **8/9** and **11/12**,<sup>12</sup> besides the expected compounds **7** or **10**, respectively. Formation of these by-products gave clear-cut evidence of the existence of a ring-chain tautomerism occurring in the N-C=O grouping of the seven-membered rings (Scheme 2).

The efficiency of the procedure in the case of pure bicyclic derivative **6b** should be ascribed to its rapid isomerization<sup>10</sup> into *N,N*-methylenebis(oxazolidine) isomer **5b** via transient open-chain forms. In contrast, the slow conversion **6a** → **5a** should favour their decomposition into their parent aminoester **1a** as demonstrated for similar derivatives.<sup>13</sup> Subsequent acylation led to the by-products **8/9** or **11/12**. The overall experiments suggested that *N,N*-methylenebis(oxa- or thiazolidine) structures type **5** are the more reactive forms.



Scheme 2.

The present findings open an alternative way to prepare *N*-acyl-pseudoprolines derived from L-threonine and L-cysteine. Further investigations are in progress for the particular but not definitive case of L-serine. These results supported the expectations that *N,N*-methylenebis(oxazolidine) and 1,6-diaza-3,9-dioxabicyclo[4.4.1]undecane structures could be considered as synthetic equivalents of the non-isolable oxaprolines **4a** and **4b**. This procedure will be extended to the synthesis of pseudopeptides containing pseudoproline residues.

### Acknowledgements

The author's are grateful to the Regional Council of Reunion Island for financial support.

### References and notes

- Fülöp, F.; Pihlaja, K. *Tetrahedron* **1993**, *49*, 6701–6706.
- Fülöp, F.; Mattinen, J.; Pihlaja, K. *Tetrahedron* **1990**, *46*, 6545–6552.
- See for examples: (a) Aitken, D. J.; Guillaume, D.; Husson, H.-P.; Chiaroni, A.; Riche, C. *J. Heterocycl. Chem.* **1991**, *28*, 705–709; (b) Kostyanovsky, R. G.; El'natanov, Yu. I.; Krutius, O. N.; Chervin, I. I.; Zaddach, H.; Koehler, K. F. *Russ. Chem. Bull.* **1994**, *43*, 321–322; (c) Bolm, C.; Chuang, T.-H.; Raabe, G.; Fang, J.-M. *Synth. Commun.* **1999**, *29*, 43–51; (d) Aitken, D. J.; Besson, L.; Fournier, F.; Husson, H.-P.; Lemoine, P.; Lesage, D.; Libot, F.; Martin, P.-G.; Mellin-Morlière, C.; Monnier, V.; Tabet, J.-C.; Viossat, B. *Heterocycles* **2004**, *64*, published on line.
- See for example: Luo, Y.; Evindar, G.; Fishlock, D.; Lajoie, G. A. *Tetrahedron Lett.* **2001**, *42*, 3807–3809.
- Sélambarom, J.; Monge, S.; Carré, F.; Roque, J.-P.; Pavia, A. A. *Tetrahedron* **2002**, *58*, 9559–9566.
- Kanemasa, S.; Onimura, K. *Tetrahedron* **1992**, *48*, 8645–8658.
- Taylor, W. G.; Hall, T. S.; Schreck, C. E. *Can. J. Chem.* **1992**, *70*, 165–172.

8. (a) Kern, D.; Schutkowski, M.; Drakenberg, T. *J. Am. Chem. Soc.* **1997**, *119*, 8403–8408; (b) Nishi, T.; Fukazawa, T.; Kurata, H.; Ishibashi, K.; Nakajima, K.; Yamaguchi, T.; Itoh, K. EP-776893-A1, 1996, Sankyo Co., Ltd; (c) Nishi, T.; Fukazawa, T.; Ishibashi, K.; Nakajima, K.; Sugioka, Y.; Iio, Y.; Kurata, H.; Itoh, K.; Mukaiyama, O.; Satoh, Y.; Yamaguchi, T. *Bioorg. Med. Chem.* **1999**, *9*, 875–880.
9. Sélambarom, J.; Monge, S.; Carré, F.; Fruchier, A.; Roque, J.-P.; Pavia, A. A. *Carbohydr. Res.* **2001**, *330*, 43–51.
10. Sélambarom, J.; Carré, F.; Fruchier, A.; Roque, J.-P.; Pavia, A. A. *Tetrahedron* **2002**, *58*, 4439–4444.
11. For instance, compound **17**: FAB<sup>+</sup> MS (NBA) *m/z*: 190 [M+H]<sup>+</sup>; 212 [M+Na]<sup>+</sup>; 43 [CH<sub>3</sub>-C=O]<sup>+</sup>; 148 [M+H-CH<sub>3</sub>-C=O]<sup>+</sup>; 379 [2M+H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>; 200 MHz)  $\delta$ : (*syn*- and *anti*-rotational isomers): 2.05 and 2.19 (each s, 3H, CH<sub>3</sub>CO); 3.24 and 3.27 (each m, 2H, S-CH<sub>2</sub>-CH); 3.77 and 3.82 (each s, 3H, OCH<sub>3</sub>); 4.61 and 4.64 (each m, 2H, S-CH<sub>2</sub>-N); 4.77 and 5.12 (each dd, *J* = 5.7 Hz, *J* = 3.81 Hz and *J* = 6.6 Hz, *J* = 4.02 Hz, 1H, S-CH<sub>2</sub>-CH).
12. For instance, compound **11**: FAB<sup>+</sup> MS (NBA) *m/z*: 224 [M+H]<sup>+</sup>; 105 [Ph-C=O]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>; 200 MHz)  $\delta$ : 3.21 (br s, 1H, OH); 3.81 (s, 3H, OCH<sub>3</sub>); 4.06 (dd, *J* = 11.2 Hz, *J* = 7.5 Hz, 2H, O-CH<sub>2</sub>-CH); 4.85 (dt, *J* = 7.5 Hz, *J* = 3.5 Hz, 1H, O-CH<sub>2</sub>-CH); 7.26 (d, *J* = 11.2 Hz, 1H, NH); 7.43–7.86 (m, 5H, H-ar). Compound **12**: FAB<sup>+</sup> MS (NBA) *m/z*: 328 [M+H]<sup>+</sup>; 105 [Ph-C=O]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>; 200 MHz)  $\delta$ : 3.86 (s, 3H, OCH<sub>3</sub>); 4.80 (dd, *J* = 7.5 Hz, *J* = 3.5 Hz, 2H, O-CH<sub>2</sub>-CH); 5.21 (dt, *J* = 3.5 Hz, *J* = 3.5 Hz, 1H, O-CH<sub>2</sub>-CH); 7.14 (d, *J* = 7.3 Hz, 1H, NH); 7.40–7.94 (m, 5H, H-ar).
13. Moloney, G. P.; Iskander, M. N.; Craik, D. J. *Magn. Reson. Chem.* **1997**, *35*, 337–341.